Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub
https://doi.org/10.64483/jmph-190

Optimizing Outcomes in Lupus Nephritis Through Interdisciplinary Collaboration: The Intersection of Nursing, Family Medicine, Laboratory Science, and Medical Record Management

Shams Yousef Alamri (1) , Shroq Hadi Hassan Hamzi (2) , Majed Shwiman Alshwiman (3) , Zahi Mohammed Alqarni (4) , Samiah Saleem Alharbi (5) , Ahlam Khalaf Daher Albalawi (5) , Ahmad Khalaf Thaher Al-Balwi (5) , Hanan Ahmed Dagriri (6) , Maqbulah Ali Albalawi (7) , Shroq Hadi Hassan Hamzi (2)

(1) Ministry Of Interior, Security Forces Hospital, Saudi Arabia,
(2) Comprehensive Specialized Clinics For The Security Forces In Hail Ministry Of Interior, Saudi Arabia,
(3) Ministry Of Interior, Security Forces Hospital – Riyadh, Senior Medical Laboratory, Saudi Arabia,
(4) Ministry Of Interior, Medical Cities Program-Moi, Saudi Arabia,
(5) Ministry Of Interior, Security Forces Primary Healthcare In Tabuk, Saudi Arabia,
(6) Ministry Of Interior, Security Forces Hospital In Riyadh, Nurse, Saudi Arabia,
(7) Ministry Of Interior, Security Forces Comprehensive Specialized Clinics – Tabuk, Medical Records , Saudi Arabia

Abstract

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune complex deposition and multi-organ inflammation. Lupus nephritis (LN), a severe renal manifestation, is a leading cause of morbidity and mortality in SLE patients, with a significant risk of progression to end-stage renal disease (ESRD) if not managed promptly.
Aim: This article synthesizes the complex etiology, pathophysiology, and management of LN, with an implicit aim to underscore the necessity of a multidisciplinary, collaborative approach to optimize patient outcomes through early detection, precise diagnosis, and personalized treatment.
Methods: The review consolidates current medical literature on LN, detailing its pathogenesis involving genetic predisposition, environmental triggers, and immune dysregulation. It emphasizes the critical role of renal biopsy for histopathological classification (ISN/RPS system) and evaluation of activity/chronicity indices. The management framework is analyzed, outlining evidence-based protocols for induction and maintenance immunosuppressive therapy, risk-factor modification, and the integration of novel biologic agents.
Results: LN prognosis is highly dependent on timely intervention guided by histologic class. Proliferative forms (Classes III/IV) carry the poorest renal outcomes without aggressive treatment. Advances in therapy, including mycophenolate mofetil, belimumab, and voclosporin, have improved remission rates and enabled steroid-sparing strategies. However, outcomes are significantly influenced by factors such as ethnicity, access to care, and adherence to long-term maintenance therapy.
Conclusion: Effective management of LN requires an interdisciplinary model integrating rheumatology, nephrology, nursing, primary care, and laboratory science. This collaborative framework ensures vigilant surveillance, biopsy-informed treatment decisions, aggressive comorbidity management, and comprehensive patient education, ultimately leading to preserved renal function and improved quality of life.
Keywords: Lupus Nephritis, Systemic Lupus Erythematosus, Interdisciplinary, Collaboration, Renal Biopsy, Immunosuppressive Therapy, Chronic Kidney Disease.

1. Introduction

Systemic lupus erythematosus (SLE) is a chronic, immune-mediated disorder characterized by loss of self-tolerance, immune complex deposition, and inflammation that can affect virtually any organ system. Its diagnosis rests on a combination of clinical features and serologic evidence—most notably the detection of disease-defining autoantibodies—which together distinguish SLE from phenotypically similar rheumatologic conditions [1]. Historically, the nosology of lupus has undergone substantial revision: from Hippocrates' earliest description around 400 BCE to 18th–19th-century attributions linking the disease to infections such as tuberculosis and syphilis, culminating in the modern appreciation of SLE as a multisystemic entity rather than a purely dermatologic disorder [2]. This evolution reflects advances in immunology and pathology that have clarified the systemic nature of tissue injury and the centrality of autoantibody-mediated mechanisms in disease expression [3]. Among the most consequential organ manifestations is renal involvement, termed lupus nephritis, which substantially drives long-term morbidity and mortality. Although the clinical course

*Corresponding author e-mail: Shams92alamri@Outlook.Sa (Shams Yousef Alamri).
Receive Date: 25 September 2025, Revise Date: 25 October 2025, Accept Date: 29 October 2025

is heterogeneous, kidney disease frequently emerges within 3 to 5 years after initial SLE onset, underscoring the need for vigilant longitudinal surveillance even in patients who are initially asymptomatic [4]. Importantly, histopathologic evidence of nephritic changes may be present despite minimal or absent clinical findings, a dissociation that justifies protocolized screening in all SLE cohorts rather than symptom-triggered testing alone [1]. Contemporary monitoring frameworks integrate serial serum creatinine measurements, urine protein-to-creatinine ratios, and urinalysis to detect evolving renal dysfunction, particularly new or worsening proteinuria that is typical of lupus nephritis [2]. The timely interpretation of these laboratory signals—paired with careful clinical assessment—enables earlier detection of inflammatory activity and facilitates prompt escalation of care to mitigate irreversible nephron loss [3]. Given the high risk of progression to end-stage renal disease (ESRD) when diagnosis and therapy are delayed, early institution of evidence-based treatment is paramount [4]. Therapeutic goals prioritize the normalization of kidney function where achievable or, at minimum, the stabilization of renal parameters to prevent further decline [5]. Because lupus nephritis comprises a spectrum of pathologic lesions with distinct immunopathologic drivers and prognostic implications, management must be individualized on the basis of histologic classification, disease chronicity, and activity indices derived from biopsy and laboratory data [6]. In this context, aligning clinical vigilance with structured laboratory surveillance offers the best opportunity to intercept renal injury trajectories early, tailor immunosuppressive strategies appropriately, and ultimately improve renal and overall outcomes in patients living with SLE [5][6].

Etiology

The pathogenesis of lupus nephritis is a complex interplay of genetic predisposition, environmental triggers, and immune dysregulation that culminates in immune complex–mediated glomerular injury. Fundamentally, lupus nephritis represents a type III hypersensitivity reaction, characterized by the deposition of circulating immune complexes in renal tissues. These complexes primarily consist of anti-double-stranded DNA (anti-dsDNA) antibodies bound to nuclear antigens, including chromatin fragments released during apoptosis or defective clearance of cellular debris. When these immune complexes localize in the mesangium, subendothelial, or subepithelial zones of the glomerular basement membrane, they provoke complement activation and a cascade of inflammatory events [7]. The complement system, particularly C1q, C3, and C4, becomes consumed during this process, facilitating leukocyte recruitment and the release of proinflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). The resulting oxidative stress, endothelial damage, and mesangial proliferation lead to the structural and functional alterations characteristic of lupus nephritis.

Genetic Factors

Genetic predisposition is one of the most critical determinants of susceptibility to systemic lupus erythematosus (SLE) and its renal complications. The loss of immunological self-tolerance, a hallmark of autoimmune diseases, is widely considered to be polygenic in origin, influenced by multiple interacting loci. More than 50 genetic polymorphisms have been implicated in the development of lupus nephritis, encompassing genes involved in immune regulation, complement activation, and apoptotic pathways [7]. Among these, polymorphisms in platelet-derived growth factor receptor-alpha (PDGFRA), apolipoprotein L1 (APOL1), and hyaluronan synthase 2 (HAS2) have been repeatedly associated with increased susceptibility. Additionally, certain human leukocyte antigen (HLA) alleles—particularly HLA-DR3 and HLA-DR15—confer elevated risk, especially among individuals of European ancestry, while HLA-DR4 and HLA-DR11 are associated with relative protection [7]. These associations underscore the central role of antigen presentation and adaptive immune responses in disease pathogenesis. Familial clustering of SLE further strengthens the genetic hypothesis. Epidemiologic studies have demonstrated a familial prevalence of approximately 10–12%, with markedly higher concordance rates among monozygotic twins (25–57%) compared with dizygotic twins (2–9%) [8][9]. Such data confirm a substantial heritable component but also highlight the influence of non-genetic factors, as perfect concordance is absent even among identical twins. This indicates that environmental exposures, infections, and epigenetic modifications likely serve as necessary cofactors in triggering disease expression within genetically susceptible hosts.

Molecular and Genetic Variants

Several key gene variants have been mechanistically linked to lupus nephritis through their effects on innate and adaptive immune pathways. The IFIH1 gene, encoding melanoma differentiation–associated protein 5 (MDA5), acts as a cytoplasmic sensor for double-stranded RNA. Variants in IFIH1 enhance RNA binding affinity, leading to hyperactivation of type I interferon (IFN) signaling, a pathway intimately involved in SLE pathogenesis. Patients carrying these risk alleles often display exaggerated IFN signatures and a higher prevalence of anti-dsDNA antibody formation, which directly contribute to immune complex deposition in the kidneys [10].

Another critical gene, ITGAM, encodes CD11b-integrin (αM), a subunit of the Mac-1 (αMβ2) complex expressed on macrophages, neutrophils, and dendritic cells. This integrin mediates phagocytosis and the clearance of immune complexes, and its dysregulation impairs innate immune tolerance, promoting inflammation and tissue injury [8]. Similarly, polymorphisms in the FCGR gene family, which encode Fc gamma receptors (FcγRs) responsible for binding immunoglobulin G (IgG) immune complexes, disrupt the normal clearance of these complexes and perpetuate glomerular deposition [8][9]. The APOL1 and FcγRIIa variants have been identified as particularly relevant among individuals of African descent, correlating with both higher prevalence and greater severity of lupus nephritis [7]. These findings reflect population-specific genetic vulnerabilities that modulate immune response thresholds and inflammatory potential. Collectively, these genetic factors do not operate in isolation but instead converge on shared pathogenic mechanisms—namely, aberrant immune complex clearance, hyperactivation of interferon pathways, and complement-mediated tissue injury. This convergence underscores the multifactorial and polygenic architecture of lupus nephritis. Continued genomic and transcriptomic investigations promise to refine our understanding of these molecular underpinnings, paving the way for precision-based diagnostic and therapeutic strategies tailored to individual genetic and immunologic profiles [8][9][10].

Environmental Factors

Environmental triggers play a critical role in the onset and exacerbation of systemic lupus erythematosus (SLE) and its renal manifestation, lupus nephritis. While genetic predisposition establishes susceptibility, environmental stimuli often act as the precipitating factors that convert latent autoimmunity into clinically overt disease. These triggers promote immune dysregulation through mechanisms such as molecular mimicry, oxidative stress, epigenetic modification, and direct tissue injury. Among the numerous environmental influences implicated, ultraviolet (UV) radiation, air pollution, alterations in the gut microbiome, and viral infections are the most substantiated contributors [11][12][13].

Ultraviolet Radiation and Air Pollution

Ultraviolet (UV) light sensitivity is one of the most well-documented environmental phenomena in lupus pathogenesis. Studies suggest that up to 80% of SLE patients exhibit photosensitivity, and skin exposure to UV light frequently precipitates both cutaneous lesions and systemic disease flares [11]. Mechanistically, UV radiation induces keratinocyte apoptosis, leading to the release of nuclear antigens such as DNA and histones. These extracellular nuclear components become immunogenic targets for anti-dsDNA antibodies, perpetuating immune complex formation and deposition. Furthermore, UV exposure stimulates neutrophilic infiltration within the skin, promoting local inflammation. Neutrophils, however, are not confined to the dermal milieu; evidence indicates their migration to renal tubulointerstitial spaces, where they amplify the inflammatory milieu and contribute to glomerular injury. This phenomenon exemplifies the "skin–kidney axis," whereby inflammatory processes initiated in the skin may propagate systemically and exacerbate lupus nephritis [12]. Recent studies have expanded this paradigm by linking air pollution to disease activity and renal involvement in SLE. Chronic exposure to airborne particulates such as nitrogen dioxide (NO_2), ozone (O_3), and particulate matter (PM2.5) is associated with increased oxidative stress and immune activation. Pollutants can enhance antigen presentation, upregulate toll-like receptor expression, and impair macrophage clearance of apoptotic debris—all processes central to lupus immunopathogenesis. This interplay between UV radiation, atmospheric pollutants, and systemic inflammation reinforces the concept that environmental oxidative stressors can potentiate lupus flares and renal complications through synergistic immunologic pathways [13].

Gut Microbiome and Intestinal Permeability

Another emerging area of environmental influence in SLE involves gut microbiota dysregulation. The human gut harbors a complex microbial ecosystem that modulates both local and systemic immune responses. In lupus, disruptions in microbial diversity and composition—particularly an increased Bacteroides/Firmicutes ratio—have been observed, suggesting a pathogenic shift toward a pro-inflammatory state [14]. This dysbiosis may lead to increased intestinal permeability, allowing bacterial products such as lipopolysaccharides (LPS) and peptidoglycans to translocate into the bloodstream. These microbial antigens can engage pattern recognition receptors, activate dendritic cells, and initiate molecular mimicry, in which microbial peptides resemble self-antigens, thereby triggering autoantibody formation [15]. In addition to bacterial components, food antigens may modulate immune activity by altering gut permeability and immune tolerance. Dietary antigens from gluten, casein, and certain preservatives have been hypothesized to elicit or exacerbate autoimmune reactions in predisposed individuals. Although the evidence remains preliminary, it underscores the importance of the gut–immune axis in SLE pathophysiology. Further investigation into microbiome modulation—through diet, probiotics, or antibiotics—may reveal novel preventive or therapeutic strategies for lupus nephritis [16].

Viral Infections

Viral pathogens have long been recognized as pivotal environmental triggers in lupus development and exacerbation. Among them, Epstein–Barr virus (EBV), parvovirus B19, and human endogenous retroviruses (HERVs) are the most extensively studied. EBV, for example, establishes latent infection in B lymphocytes and can induce polycolonal B-cell activation and autoantibody production through the expression of viral nuclear antigens that mimic self-DNA and histones [17]. Similarly, parvovirus B19 infection has been linked to lupus flares via cross-reactive immune responses and the induction of type I interferon pathways. More recently, the global pandemic caused by SARS-CoV-2 has revealed another viral connection. Case reports and cohort studies have described instances of de novo SLE and lupus nephritis developing after COVID-19 infection [18]. The proposed mechanism involves molecular mimicry between viral proteins and host autoantigens, leading to an aberrant immune response that persists beyond viral clearance. Moreover, the cytokine storm associated with severe COVID-19 infection may unmask subclinical autoimmunity or exacerbate preexisting disease.

Immune System Dysregulation

Immune system dysregulation in systemic lupus erythematosus (SLE) and its renal manifestation, lupus nephritis, reflects a multilayered failure of immune tolerance that spans innate and adaptive arms. At its core, lupus nephritis is a prototypical type III hypersensitivity process in which autoantibodies directed against nuclear constituents assemble into circulating immune complexes that lodge within the glomerular filtration apparatus. These complexes form either in the circulation or in situ after antibodies bind "planted" antigens within the mesangium and along subendothelial or subepithelial surfaces of the glomerular basement membrane, initiating complement activation and leukocyte recruitment that drive tissue injury [9][19]. In parallel, antiphospholipid antibodies—common in a subset of SLE—promote microvascular thrombosis by targeting negatively charged phospholipid–protein assemblies, thereby superimposing ischemic damage on immune complex–mediated inflammation, a dual hit that is particularly relevant in antiphospholipid syndrome–associated nephropathy [20]. The autoantibody repertoire in SLE is diverse and dynamic. Anti–double-stranded DNA (anti-dsDNA) antibodies are a hallmark, reflecting the immune system's response to extracellular chromatin derived from apoptotic cells; nucleosome-containing immune complexes subsequently deposit in glomeruli and the interstitium, where they activate complement and stimulate resident and infiltrating immune cells [9][19]. Notably, clinical and translational studies indicate that other specificities—such as anti-enolase-1 and anti-histone-2—may correlate even more strongly with renal involvement, underscoring the heterogeneity of pathogenic drivers within the broader anti-nuclear antibody pool [20][21]. Additional autoantibodies, including anti-C1q, anti-nucleosome, anti-α-actinin, and anticardiolipin, participate in overlapping and sometimes synergistic ways; for example, anti-α-actinin can interact with anti-dsDNA to yield higher-affinity complexes with enhanced glomerular avidity, amplifying local inflammation and structural damage [20].

Disease evolution frequently reflects "epitope spreading," wherein an initial, relatively narrow autoreactive response broadens to incorporate additional epitopes on the same antigen and eventually distinct molecules. In the kidney, this immunologic broadening is mirrored by a topographic progression of immune deposits: early mesangial-predominant involvement (class I/II) gives way to subendothelial and subepithelial deposition that characterizes proliferative lesions (class III/IV), often accompanied by endocapillary hypercellularity, necrosis, and crescent formation [20]. The expanding epitope repertoire increases both the density and the diversity of deposited immune complexes, sustaining complement activation and perpetuating a feed-forward loop of injury. Innate immune mechanisms orchestrate much of this amplification. Neutrophils, primed by immune complexes and Fc receptor engagement, release neutrophil extracellular traps (NETs)—chromatin lattices decorated with granular proteins—that not only incite local cytotoxicity but also provide additional nuclear antigen to maintain the anti-nuclear response. Anti-dsDNA antibodies themselves can stimulate NETosis, creating a self-reinforcing cycle of antigen supply and autoantibody production [21]. Bone marrow and extramedullary granulopoiesis contribute to neutrophil excess, while mononuclear phagocytes undergo a phenotypic shift from efficient efferocytosis toward antigen presentation, diminishing clearance of apoptotic debris and fostering persistent exposure to nuclear autoantigens [9]. Dendritic cells, particularly plasmacytoid subsets, sense nucleic acid–containing immune complexes through endosomal Toll-like receptors and secrete type I interferons (IFN-I), which further lower B-cell activation thresholds and prime T-cell responses, thereby linking innate sensing to adaptive autoimmunity and fibrogenic pathways in the kidney [9].

Adaptive immunity consolidates these signals into durable autoreactivity. B cells not only generate autoantibodies but also act as antigen-presenting cells and cytokine producers. T-follicular helper (Tfh) cells expand in active SLE and provide potent help to autoreactive B cells within germinal centers and ectopic lymphoid aggregates, while T-regulatory (Treg) cell numbers and function are relatively diminished, shifting the Tfh:Treg balance toward pathogenic humoral immunity. This imbalance is particularly pronounced in proliferative lupus nephritis (classes III and IV), where circulating Tfh cells correlate with disease activity and renal inflammation [18][22]. Within the kidney microenvironment, resident cells, including mesangial cells, podocytes, and tubular epithelial cells, are not passive targets. They respond to cytokines and immune complexes with chemokine secretion, antigen presentation, and matrix remodeling; podocytes, in particular, are injured by complement split products and oxidative stress, culminating in foot-process effacement and proteinuria that characterize clinical flares [19][22]. Cytokine networks cement these pathological interactions. Type I interferons upregulate BAFF (B-cell activating factor) signaling pathways that sustain autoreactive B-cell survival and class switching. Tubular epithelial cells can themselves produce BAFF, fostering the formation of tertiary lymphoid structures within the interstitium that perpetuate local autoantibody production and antigen presentation; BAFF is therefore an attractive therapeutic target in renal SLE and has spurred interventional studies exploring pathway blockade [23]. Additional mediators—such as IL-6, IL-21, and TGF-β—contribute to plasma cell differentiation, fibrosis, and progressive loss of renal function, providing mechanistic rationale for combined immunomodulatory approaches in severe disease [22][23].

Complement activation is both a trigger and an effector arm of injury. Although classical pathway engagement by immune complexes is a canonical feature, robust evidence indicates that all three pathways—classical, lectin, and alternative—participate in renal damage. Clinically, low serum C3 often tracks more closely with disease activity in lupus nephritis than low C4, implicating the alternative pathway's amplification loop in sustaining complement activation within glomeruli [18]. Generation of C3a and C5a recruits and activates leukocytes, while assembly of the membrane attack complex (C5b-9) on podocytes and endothelial cells induces sub-lethal injury, cytoskeletal rearrangement, and prothrombotic surface changes. In patients with concurrent antiphospholipid antibodies, complement-driven endothelial activation intersects with antibody-mediated coagulation pathway perturbations to promote glomerular capillary thrombosis and cortical ischemia, worsening outcomes despite control of conventional immune complex activity [20]. Beyond classical immune pathways, metabolic and environmental modulators shape disease severity. Vitamin D exerts broad immunoregulatory effects, including inhibition of dendritic cell maturation, promotion of Treg development, and attenuation of B-cell proliferation. Observational studies in SLE consistently associate lower 25-hydroxyvitamin D3 levels with heightened disease activity and increased risk of nephritis, with an inverse relationship between vitamin D status and flare propensity; however, causality is difficult to parse, in part because photosensitivity and medical advice to avoid sun exposure may depress cutaneous synthesis of vitamin D in this population [18][24]. These data nonetheless suggest that vitamin D repletion could complement immunosuppressive regimens, though definitive interventional evidence remains an area of ongoing research [24].

Epidemiology

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a highly variable epidemiologic profile influenced by age, gender, ethnicity, and geographic distribution. Although SLE can affect individuals of all ages and backgrounds, it shows a striking predilection for women of childbearing age and certain ethnic populations. Among its many complications, lupus nephritis represents one of the most clinically significant due to its impact on long-term renal and overall survival outcomes. Approximately 40% of patients with SLE develop lupus nephritis, making it the most frequent cause of secondary glomerulonephritis worldwide [18]. Despite advances in immunosuppressive therapy, about 10% to 30% of affected individuals will progress to end-stage renal disease (ESRD) within a decade of diagnosis, underscoring the serious nature of renal involvement in lupus and the need for early diagnosis and aggressive management [18].

Age-Related Trends

Lupus nephritis typically emerges early in the course of systemic lupus erythematosus and most often affects individuals between the ages of 20 and 40, coinciding with the peak incidence of SLE itself [25]. The onset of lupus nephritis during this period is particularly concerning, as it coincides with the most productive and reproductive years of life, thereby amplifying the disease's psychosocial and economic burden. Notably, pediatric-onset SLE tends to follow a more severe trajectory compared with adult-onset cases. Children and adolescents with lupus exhibit higher frequencies of renal involvement, often presenting with proteinuria, hematuria, and hypertension earlier in the disease course [26]. The reasons for increased renal involvement among pediatric patients are multifactorial. Genetic susceptibility heightened immune reactivity, and delayed recognition of early clinical signs contribute to the aggressive nature of childhood lupus nephritis. Furthermore, disease activity and cumulative organ damage are often greater in this population, which may be compounded by challenges in medication adherence, growth-related pharmacokinetics, and hormonal changes during puberty [25][26]. Consequently, pediatric patients with lupus nephritis require more vigilant monitoring and often more intensive immunosuppression to prevent irreversible renal damage and progression to ESRD.

Gender-Related Distribution

One of the defining features of SLE and lupus nephritis is their strong gender bias. Women constitute approximately 90% of all SLE patients, resulting in a female-to-male ratio of about 9:1 [27]. This disproportionate prevalence is largely attributed to the immunomodulatory effects of estrogen, which promotes B-cell hyperactivity, autoantibody production, and type I interferon responses—all central to lupus pathogenesis. Conversely, androgens may exert a protective effect by suppressing immune activation, explaining the lower disease frequency in men. Despite their lower incidence, men with SLE often experience a more aggressive disease course, particularly in relation to renal manifestations. Studies have shown that male patients present with higher rates of lupus nephritis, greater degrees of proteinuria, and poorer renal outcomes compared to their female counterparts [27]. This paradox—lower prevalence but more severe expression—suggests that once the protective hormonal influence is lost or overridden, male patients may be predisposed to a more inflammatory disease phenotype. Hormonal factors, differences in immune cell gene expression, and variations in healthcare-seeking behavior may collectively contribute to this gender disparity in disease severity [27].

Ethnicity-Related Patterns

Ethnic background significantly influences both the prevalence and clinical expression of SLE and lupus nephritis. The disease is notably more prevalent among Hispanic, Black, and Asian populations compared to White populations, with the highest rates observed in Caribbean populations [28]. The reasons for these disparities are multifactorial, encompassing genetic, socioeconomic, and environmental factors. Polymorphisms in genes such as APOL1, HLA-DRB1, and Fcγ receptor genes contribute to the heightened susceptibility and poorer renal outcomes observed in individuals of African and Hispanic ancestry [7]. Among patients with SLE, Asian populations demonstrate a particularly high prevalence of lupus nephritis. However, despite higher incidence rates, Asian patients tend to achieve better 10-year renal survival and overall outcomes than their White or Black counterparts [18][28]. This improved prognosis has been attributed to earlier disease detection, greater treatment adherence, and genetic factors that may modulate immune response and therapeutic efficacy. In contrast, Black and Hispanic patients with SLE often present with more severe renal impairment at diagnosis, reflected in higher serum creatinine levels and more pronounced proteinuria compared with White patients [7]. Socioeconomic determinants—including access to healthcare, comorbid conditions, and treatment disparities—exacerbate these outcomes. In addition, environmental stressors such as chronic psychosocial stress and exposure to urban pollutants may amplify systemic inflammation, accelerating renal damage in genetically susceptible individuals [28].

Global and Socioeconomic Considerations

Globally, SLE and lupus nephritis show regional variation in incidence and outcomes. Higher rates are reported in North America, the Caribbean, and parts of Asia, whereas lower rates are seen in Europe and sub-Saharan Africa. These patterns may reflect differences in genetic background, environmental exposures, healthcare infrastructure, and diagnostic capacity. In high-income countries, earlier diagnosis and access to immunosuppressive therapy have improved renal outcomes and survival, though disparities persist among ethnic minorities even within these healthcare systems [18]. Overall, lupus nephritis represents a significant contributor to morbidity and mortality in patients with SLE across all populations. Its epidemiology underscores the intersection of biological, environmental, and social determinants of health. Recognizing the influence of age, gender, and ethnicity is essential for designing tailored screening strategies, ensuring equitable access to care, and guiding the development of targeted therapies aimed at improving renal outcomes in this heterogeneous and complex autoimmune disease [7][18][25][26][27][28].

Pathophysiology

Lupus nephritis arises from a convergence of glomerular, tubulointerstitial, and vascular immune injuries that together determine clinical expression and long-term renal outcomes. In systemic lupus erythematosus (SLE), circulating and in situ–formed immune complexes trigger complement activation and leukocyte recruitment within the kidney, producing mesangial hypercellularity, endocapillary proliferation, necrosis, crescents, and podocyte injury in variable combinations. Clinically, kidney involvement develops in roughly 40% of patients—often within five years of SLE diagnosis—and 10% to 30% progress to end-stage renal disease (ESRD) by 10 years despite contemporary therapy, emphasizing the need for accurate classification and timely, targeted treatment [18]. Presentation spans a spectrum from asymptomatic urinary abnormalities to overt nephritic or nephrotic syndromes, and disease activity typically attenuates over time as immune injury gives way to scarring; nevertheless, smoldering activity can persist and drive cumulative damage if not recognized and controlled [29][30]. Renal biopsy is therefore foundational to diagnosis and risk stratification, because histopathologic patterns carry distinct therapeutic implications. Indications for biopsy commonly include a urine protein-to-creatinine ratio exceeding 500 mg per 24 hours (or persistent subnephrotic proteinuria with active urinary sediment), unexplained or progressive renal dysfunction, or dysmorphic hematuria with casts. Tissue assessment integrates light microscopy, immunofluorescence, and electron microscopy to define the topography and intensity of immune deposition and to quantify both active inflammation and chronic injury (interstitial fibrosis and tubular atrophy), thereby anchoring management to objective pathology rather than serology or urinary indices alone [29][30].

The current standardized classification—derived from successive World Health Organization (WHO) frameworks and refined by the International Society of Nephrology/Renal Pathology Society (ISN/RPS)—categorizes lupus nephritis into six classes based on glomerular morphology and the distribution of immune deposits. In class I, or minimal mesangial lupus nephritis, glomeruli appear normal by light microscopy, but immunofluorescence reveals mesangial immune complexes; clinical correlates are often subtle, and prognosis is generally excellent when renal function is preserved [29]. Class II, proliferative mesangial disease, features mesangial hypercellularity and matrix expansion with mesangial immune deposition; it typically manifests as microscopic hematuria and low-grade proteinuria with normal creatinine, although evolution to more aggressive classes can occur, meriting surveillance for superimposed activity [29][31]. Classes III and IV—focal and diffuse proliferative lupus nephritis—represent the major proliferative phenotypes and the principal determinants of long-term renal risk. Class III involves fewer than 50% of glomeruli with segmental or global endocapillary hypercellularity, subendothelial "wire-loop" immune deposits, necrosis, and crescents; class IV extends these lesions to 50% or more of glomeruli, often with greater intensity and chronicity indices. Immunofluorescence demonstrates mesangial and capillary wall deposits, and electron microscopy confirms mesangial, subendothelial, and sometimes subepithelial immune complexes. Clinically, hematuria, proteinuria, reduced glomerular filtration, and hypertension predominate, and serologic activity (high anti–dsDNA, low complement) is common. Class IV is the most frequent and confers the worst short- and long-term prognosis; meta-analytic data indicate that 15% to 30% of patients fail to achieve remission, and among those who do, 15% to 30% subsequently relapse, highlighting a pattern of refractory or recurrent inflammation that requires meticulous induction and maintenance strategies [29][31].

Class V, membranous lupus nephritis, is characterized by prominent subepithelial immune complex deposition and thickened capillary loops with or without mesangial involvement. Podocyte injury and effacement of foot processes produce nephrotic-range proteinuria, hyperlipidemia, and edema, while serum creatinine may be only mildly elevated at presentation. Class V can occur alone or in combination with class III or IV lesions, the latter combination portending a more complex clinical course because nephrotic physiology intersects with proliferative activity to increase both thrombotic and infectious risks [29]. Class VI, advanced sclerosing lupus nephritis, reflects end-stage scarring in at least 90% of glomeruli, often with minimal residual immune deposition due to replacement by matrix; biopsy in this context is less common because patients frequently present with established ESRD, but when performed it confirms irreversible chronic damage and redirects management toward renal replacement and transplant planning [29][31]. Across classes, the tubulointerstitium and vasculature critically modulate outcomes. Interstitial inflammation and tubular epithelial injury correlate strongly with progressive loss of function, while chronic interstitial fibrosis and tubular atrophy are powerful predictors of nonrecovery even after immunologic quiescence. Vascular lesions range from immune complex–mediated capillaritis and endothelial swelling to true thrombotic microangiopathy, particularly in patients with antiphospholipid antibodies, compounding ischemic injury on top of immune complex–driven inflammation. These lesions help explain discordances between glomerular histology and clinical phenotype and underscore why biopsy evaluation must extend beyond glomeruli to interstitial and vascular compartments to accurately stage risk and tailor therapy [29][31]. Epidemiologic patterns intersect with pathophysiology to influence natural history. Because lupus nephritis frequently arises within the first five years of SLE, the window for intercepting aggressive proliferative classes is early; once chronicity indices accumulate, responsiveness declines and the trajectory bends toward ESRD. Even with remission, relapse remains a significant threat in class IV disease, and cumulative flares accelerate scarring through cycles of active injury and incomplete repair, consistent with the observed 10% to 30% 10-year ESRD rate in unselected cohorts [18][29]. Clinically, some patients manifest only asymptomatic urinary abnormalities, yet the histologic burden can be substantial; conversely, overt nephritic or nephrotic presentations may coexist with limited chronic damage if recognized promptly, arguing for a low threshold to biopsy when clinical or serologic activity emerges [30][31].

Beyond renal outcomes, lupus nephritis amplifies systemic vascular risk. Persistent inflammation, immune complex deposition within the vasculature, complement activation, and treatment-related metabolic effects converge to accelerate atherosclerosis. Coronary artery disease (CAD) becomes the leading cause of death among individuals living more than five years with SLE, and the risk of fatal myocardial infarction is approximately threefold higher than in age-matched controls. Mechanistic contributors include endothelial dysfunction, vasculitis, thrombosis related to antiphospholipid antibodies, embolization from cardiac and vascular lesions, and vasospasm—processes that are accentuated in patients with renal involvement, hypertension, and dyslipidemia typical of nephrotic states [32]. These cardiovascular risks necessitate integrated management that addresses not only immunologic activity but also blood pressure, lipid profiles, glycemic control, and antithrombotic strategies when indicated.

Histopathology

The histopathology of lupus nephritis reflects the convergent effects of circulating and in situ–formed immune complexes, complement activation, and downstream inflammatory and fibrotic remodeling across all renal compartments. Which histologic phenotype emerges in a given patient is shaped by the antigenic specificity and avidity of autoantibodies, the physicochemical properties and size of the immune complexes they form, and host factors that tune the inflammatory response, repair pathways, and fibrosis. In severe forms, proliferation of endothelial, mesangial, and epithelial (podocyte and parietal epithelial) cells is accompanied by extracellular matrix accumulation, culminating in segmental and global glomerulosclerosis and interstitial scarring. Across this spectrum, characteristic immune deposits are frequently demonstrable: immunoglobulins of multiple isotypes—IgG, IgA, and IgM—together with complement components C1q, C3, and, in many cases, properdin, localize to mesangial, subendothelial, and subepithelial zones and are often accompanied by interposed inflammatory leukocytes. The resulting "full-house" pattern by immunofluorescence is a hallmark that integrates with light microscopy and electron microscopy to define class, activity, and chronicity in a manner that informs prognosis and therapy [30][33]. The standardized framework for interpreting these findings has evolved from early World Health Organization proposals to the current International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification. This system anchors diagnosis in glomerular morphologic features under light microscopy, documents the distribution and intensity of immune deposits by immunofluorescence, and confirms the ultrastructural location and character of deposits by electron microscopy. In 2018, the ISN/RPS introduced quantitative refinements that formalized scoring of active and chronic lesions, improving reproducibility and prognostic resolution across centers and studies [30][33]. As a result, renal biopsy is not merely confirmatory; it is the indispensable tool that translates the immunobiology of systemic lupus erythematosus into a graded map of renal injury.



Figure-1: Lupus Nephritis, Class II. Hematoxylin and eosin staining at ×400 magnification.

In class I, minimal mesangial lupus nephritis, glomeruli appear morphologically normal on light microscopy; however, immunofluorescence reveals mesangial immune complex deposition, and electron microscopy can detect corresponding mesangial electron-dense deposits. Podocyte foot process effacement may be present but is typically limited. The paucity of proliferative change explains the frequently subtle clinical expression of this class, which may present with no more than microscopic urinalysis abnormalities. Class II, mesangial proliferative lupus nephritis, extends this pattern: mesangial hypercellularity and matrix expansion are visible by light microscopy, while immunofluorescence again highlights mesangial deposition without subendothelial or subepithelial deposits. A practical morphologic criterion often used is the identification of at least four mesangial nuclei fully surrounded by matrix in nonhilar mesangium, a threshold that helps distinguish true mesangial proliferation from focal accentuation. Proteinuria and hematuria are common correlates, yet renal function frequently remains intact at this stage [33]. Classes III and IV—the focal and diffuse proliferative variants—encapsulate the most aggressive inflammatory phenotypes. Both are defined by endocapillary hypercellularity that may be segmental or global within the involved glomeruli, together with the cardinal presence of immune complex deposition in mesangial, subendothelial, and sometimes subepithelial locations. Class assignment is based on the fraction of glomeruli involved: fewer than 50% in class III and 50% or more in class IV. Light microscopy in these classes often discloses endothelial swelling, capillary luminal occlusion by proliferating cells and infiltrating leukocytes, karyorrhexis, fibrinoid necrosis, and crescents. Immunofluorescence reveals granular capillary-wall and mesangial staining for IgG, IgA, IgM, C3, and C1q in variable combinations, while electron microscopy confirms abundant subendothelial deposits that can bulge the capillary wall into classic "wire loop" configurations—one of the most recognizable indicators of renal activity in lupus. The diffuse pattern (class IV) is the most prevalent and carries the highest risk of short- and long-term kidney failure, a reality that has been consistently reproduced in cohort studies and meta-analyses and underlies its designation as the most ominous class from a prognostic standpoint [29][31][33].

Class V, membranous lupus nephritis, emphasizes subepithelial immune complex deposition along the outer aspect of the glomerular basement membrane. The resulting spike formation and basement membrane thickening produce a uniform capillary wall ribboning on light microscopy and granular capillary immunofluorescence with attendant mesangial staining; electron microscopy identifies discrete subepithelial electron-dense deposits often accompanied by podocyte foot process effacement. The clinical corollary is nephrotic-range proteinuria with variable degrees of renal insufficiency. Importantly, class V can coexist with class III or IV lesions, a mixed pattern that complicates management because the nephrotic physiology of membranous disease overlays the inflammatory proliferation of the focal or diffuse class. Class VI, advanced sclerosing lupus nephritis, represents end-stage scarring, with global or segmental sclerosis in at least 90% of glomeruli; in this burned-out phase, immune deposits are often no longer detectable by immunofluorescence because functional glomerular architecture has been replaced by matrix, and the biopsy serves chiefly to confirm chronic irreversibility and guide nonimmunosuppressive management [33]. The lexicon used to describe lesions—particularly in classes III and IV—matters for both scoring and clinical decision-making. Crescents are defined as extracapillary hypercellularity that occupies 10% or more of the circumference of Bowman's capsule; they are subclassified by composition into cellular (more than 75% cells and fibrin), fibrocellular (25–75% cells and fibrin with a fibrous matrix), and fibrous (more than 75% fibrous matrix) crescents. Cellular crescents signal active, potentially reversible capillary wall rupture; fibrous crescents, in contrast, denote chronic, largely irreversible damage. Adhesions are areas of continuous extracellular matrix that tether the glomerular tuft to Bowman's capsule even when overt segmental sclerosis is not present, often marking prior capillary wall injury that has healed with scarring. Fibrinoid necrosis is identified by fibrin deposition associated with glomerular basement membrane disruption or mesangial matrix lysis; it represents a fulminant active lesion that, while reminiscent of antineutrophil cytoplasmic antibody–associated vasculitis, occurs in lupus in the context of immune complex injury. Tubulointerstitial inflammation is commonly present and must be reported explicitly as occurring with or without concurrent fibrosis, because the quantity and chronicity of interstitial lesions are powerful predictors of renal outcome independent of glomerular class [33].



Figure-2: Lupus Nephritis, Class III. Hematoxylin and eosin–stained sections at ×400 magnification.

Recognizing that histologic descriptors vary in their implications for immediate treatment and long-term prognosis, the 2018 ISN/RPS update codified activity and chronicity indices. The activity index (0–24) aggregates semiquantitative scores for endocapillary hypercellularity, neutrophils and/or karyorrhexis, fibrinoid necrosis, hyaline "wire loop" deposits or hyaline thrombi, cellular or fibrocellular crescents, and interstitial inflammation. Each category is scored 0–3 based on the fraction of glomeruli or cortical area involved; because fibrinoid necrosis and cellular/fibrocellular crescents particularly reflect fulminant capillary injury, their scores are doubled in the total, emphasizing their clinical gravity. The chronicity index (0–12) sums the extent of global or segmental glomerulosclerosis, fibrous crescents, tubular atrophy, and interstitial fibrosis, each likewise graded from 0 to 3. Together, these indices distinguish potentially reversible inflammatory activity from established structural damage, providing a common language to track response over time and to stratify risk in clinical trials and practice [33]. These scores convey more than numeric abstraction. A high activity index correlates with brisk serologic activity, heavy proteinuria and hematuria, and rapid decline in filtration rate; it forecasts the need for immunosuppressive induction and predicts the likelihood of short-term remission when coupled with appropriate therapy. In contrast, the chronicity index integrates the residue of prior flares and incomplete repair, quantifying the scarring that limits functional recovery even if inflammation is quelled. Across multiple cohorts, a higher chronicity index portends worse renal survival and a muted response to therapy, with particularly strong contributions from tubular atrophy and interstitial fibrosis—lesions that mirror final common pathways of nephron loss in chronic kidney disease [34][35]. In day-to-day practice, these indices refine clinician judgment: a patient with high activity and low chronicity may be an excellent candidate for aggressive induction aimed at organ salvage, whereas high chronicity, even with modest activity, warns that expectations for recovery should be tempered and that supportive measures to slow further decline must be prioritized alongside carefully selected immunomodulation.

Immunofluorescence and electron microscopy deepen this risk portrait. The "full-house" staining pattern—simultaneous positivity for IgG, IgA, IgM, C3, and C1q—supports a diagnosis of lupus nephritis in the proper clinical context and signals robust immune complex deposition. Subendothelial deposits visible by electron microscopy often pair with endocapillary hypercellularity on light microscopy and low complement levels clinically; these deposits are also the substrate for wire loop lesions, which are not merely iconic but function as histologic barometers of active disease. Mesangial deposits alone align with mesangial classes and milder phenotypes, whereas the appearance of subepithelial deposits, particularly in organized rows along the outer glomerular basement membrane, should prompt consideration of membranous features and the attendant risk of nephrotic syndrome. Podocyte foot process effacement, while not specific to lupus, conveys the hemodynamic and permeability consequences of immune injury and explains the magnitude of proteinuria in membranous and mixed classes [33]. The tubulointerstitial compartment likewise deserves meticulous attention. Interstitial leukocytic infiltrates reflect cytokine-driven recruitment by injured tubular epithelial and endothelial cells and may form tertiary lymphoid structures that perpetuate local autoantibody production and antigen presentation. When inflammation resolves incompletely, fibroblast activation and extracellular matrix deposition ensue, producing interstitial fibrosis and tubular atrophy that are often irreversible. These lesions can dissociate from glomerular findings—patients with substantial interstitial disease may have only modest glomerular proliferative features—hence the explicit scoring of interstitial processes in the 2018 framework. Vascular changes, including immune complex capillaritis and thrombotic microangiopathy, intersect with glomerular injury to compromise perfusion and accelerate nephron dropout; their recognition helps explain refractory hypertension, abrupt kidney function declines, and the need to evaluate for antiphospholipid antibodies and complement-amplifying states [33][34].

From a pathophysiologic vantage, the histologic tableau is a time-stamped imprint of immunologic events unfolding within the kidney. Early mesangial deposition is consistent with lower-affinity or smaller complexes and robust mesangial clearance, whereas the appearance of subendothelial deposits and endocapillary proliferation indicates more substantial immune complex burden and complement activation sufficient to disrupt the endothelial–glycocalyx interface. Crescents signify capillary wall rupture and Bowman's capsule activation; abundant fibrinoid necrosis implies explosive necroinflammation. With time—and particularly after repeated flares—matrix accumulation, capillary loop obliteration, and interstitial scarring dominate, shrinking the pool of salvageable nephrons. It is this dynamic evolution that the class system and the activity/chronicity indices capture, permitting clinicians to map where a patient stands on the continuum from inflammation to sclerosis and to match therapy intensity accordingly [30][33][34]. Finally, although glomerular class guides initial therapeutic strategy, the quantification of active versus chronic lesions often calibrates expectations and informs trial eligibility and endpoints. For instance, in proliferative lupus nephritis, high-weighted activity components—fibrinoid necrosis and cellular crescents—justify urgent, potent induction to avert irreversible injury, while relatively low chronicity augurs a meaningful chance of functional recovery. Conversely, in advanced sclerosing disease, the predominance of glomerulosclerosis and tubulointerstitial scarring signals that immunosuppressive toxicity may outweigh benefit, and emphasis shifts to blood pressure control, renin–angiotensin–aldosterone system modulation, lipid management, and preparation for renal replacement therapy when appropriate. In all scenarios, careful documentation of wire loop lesions, hyaline thrombi, and interstitial inflammation provides a baseline against which response is measured on repeat biopsy when clinically indicated, anchoring longitudinal care in objective tissue biology [33][35].

History and Physical

The clinical presentation of lupus nephritis is deeply intertwined with the systemic manifestations of systemic lupus erythematosus (SLE). Since SLE is a multisystem autoimmune disease, the kidney involvement that defines lupus nephritis often develops within the broader context of widespread immune-mediated injury. However, the onset of renal disease is frequently insidious. Many patients remain asymptomatic in the early stages, with nephritis first detected through routine laboratory surveillance rather than overt clinical complaints. Recognizing subtle clues and maintaining vigilant follow-up are therefore critical to preventing irreversible renal damage and improving long-term outcomes [27][36].

Clinical History

Patients with lupus nephritis frequently exhibit a spectrum of general SLE symptoms preceding or coinciding with renal involvement. These may include malar or discoid rash, fatigue, fever, photosensitivity, serositis, oral ulcers, nonerosive arthritis, seizures, psychosis, or hematologic abnormalities such as anemia, leukopenia, or thrombocytopenia. Such systemic features often provide the first clue to the autoimmune process before renal pathology becomes evident. In some cases, however, nephritis can emerge as the initial presentation of SLE, underscoring the disease's heterogeneous nature [27]. During the early stages of lupus nephritis, patients may be entirely asymptomatic or experience only mild urinary changes. Subtle symptoms such as polyuria, nocturia, and foamy urine may reflect early proteinuria or tubular dysfunction. Proteinuria is often the earliest and most consistent laboratory marker of renal involvement. When urinary protein excretion exceeds 3.5 g/day, the patient meets the criteria for nephrotic syndrome, typically accompanied by hypoalbuminemia and peripheral edema. The edema is usually most noticeable in dependent areas, such as the ankles and periorbital region, and can progress to generalized swelling (anasarca) as the disease advances. Microscopic hematuria is also common and reflects glomerular inflammation and injury [36]. Some patients do not report symptoms at all, but routine follow-up testing for known SLE reveals abnormal findings such as elevated serum creatinine, low serum albumin, or the presence of active urinary sediment (red blood cells, white blood cells, or casts). These subclinical findings are typical in mesangial or membranous lupus nephritis, where structural injury may not yet produce significant hemodynamic compromise. As the disease progresses to diffuse proliferative lupus nephritis (class IV), renal symptoms become more apparent, and hypertension frequently develops as a consequence of glomerular and vascular injury. Hypertensive symptoms can include headache, dizziness, visual disturbances, and, in severe cases, signs of left ventricular hypertrophy or heart failure due to chronic afterload stress [27].

Physical Examination

Physical findings in lupus nephritis depend on both the underlying SLE activity and the degree of renal involvement. In focal and diffuse immune-complex–mediated forms (classes III and IV), patients often exhibit generalized lupus features such as malar rash, photosensitivity, oral or nasal ulcers, synovitis, and pleuritic or pericardial friction rubs from serositis. These manifestations reflect systemic immune activation and provide important diagnostic context for renal disease. Evidence of fluid retention is among the most common renal-specific findings. Peripheral edema typically arises from either hypoalbuminemia (due to heavy proteinuria) or salt and water retention secondary to impaired renal excretory function. Pitting edema over the ankles, shins, and sacrum is frequently seen in hospitalized patients with active nephritis. In more severe cases, generalized edema is accompanied by ascites, pleural effusions, or pericardial effusion, findings that can be appreciated on physical examination as abdominal distention, dullness to percussion, or distant heart sounds. These signs are particularly prominent in membranous lupus nephritis (class V) and in lupus podocytopathy, where nephrotic syndrome predominates in the absence of significant hypertension [36]. Blood pressure measurement is a crucial component of the physical examination. Hypertension is common in proliferative classes of lupus nephritis (III and IV), resulting from both glomerular inflammation and activation of the renin–angiotensin–aldosterone system. Chronic uncontrolled hypertension accelerates renal damage, perpetuating a vicious cycle of glomerulosclerosis and further nephron loss. Therefore, documentation of even modest elevations in blood pressure should prompt consideration of renal biopsy and therapeutic adjustment. In contrast, patients with isolated membranous lupus nephritis or podocytopathy often exhibit nephrotic features without hypertension. These include peripheral edema, ascites, and serous effusions in the pericardial or pleural spaces. Children are especially prone to lupus podocytopathy, where edema may develop rapidly in the setting of minimal change–like lesions on biopsy. Such presentations emphasize that lupus nephritis is not a uniform process but rather a diverse set of histopathologic syndromes that converge on the kidney [27][36]. More severe renal pathologies, such as collapsing glomerulopathy and thrombotic microangiopathy (TMA), although rare, can present with sudden-onset hypertension, rapidly declining renal function, and microangiopathic hemolytic anemia. Physical examination may reveal marked edema, retinopathy, or neurologic changes suggestive of hypertensive encephalopathy. Because these lesions carry a grave prognosis, renal biopsy is imperative to differentiate them from the more common immune complex–mediated variants and to guide urgent therapy [27].

Integrated Assessment

A comprehensive evaluation of lupus nephritis integrates clinical history, physical findings, and laboratory assessment. The physical examination must be contextualized within the systemic activity of SLE: the coexistence of skin lesions, arthritis, serositis, or hematologic abnormalities strengthens the suspicion that renal findings are lupus-related rather than coincidental. The presence of foamy urine, dependent edema, or new-onset hypertension should prompt immediate laboratory evaluation, including serum creatinine, urinalysis, protein quantification, and complement levels. Because lupus nephritis may evolve silently, regular surveillance—even in the absence of symptoms—is essential. This approach is particularly critical for women of childbearing age, who are disproportionately affected, and for patients of Black, Hispanic, or Asian ancestry, who are at higher risk for severe renal disease. Early detection through vigilant history-taking and examination offers the best chance to intervene before irreversible nephron loss occurs. In summary, the history and physical examination in lupus nephritis serve as the clinical foundation for diagnosis and management. While early disease may be silent, careful attention to subtle symptoms such as nocturia, foamy urine, or mild edema—combined with systematic assessment for broader SLE features—enables timely identification of renal involvement. Physical findings, especially those related to hypertension and fluid retention, reflect the underlying histologic class and disease activity, guiding the need for confirmatory biopsy and early initiation of therapy [27][36].

Evaluation

Laboratory

In the evaluation of suspected lupus nephritis, laboratory testing anchors both initial detection and longitudinal monitoring of disease activity. In active systemic lupus erythematosus (SLE), hypocomplementemia is common, with serum C3 and C4 levels typically reduced in parallel with rising titers of anti–double-stranded DNA (anti-dsDNA) autoantibodies; this serologic constellation often precedes or accompanies renal flares and helps contextualize urinary findings [37]. Serum creatinine may be normal early in the disease—despite meaningful renal inflammation—so its elevation, when present, usually indicates either substantial active injury or accrued chronic damage. Urinalysis is therefore indispensable: proteinuria, microscopic hematuria, and red blood cell casts are classic indicators of glomerular involvement, with proteinuria serving as the most sensitive routine marker of lupus nephritis activity. When urinary protein excretion exceeds 3.5 g per day, nephrotic-range proteinuria is established and typically correlates with hypoalbuminemia on a comprehensive metabolic panel, especially after sustained disease activity [37]. Because early disease may be clinically silent, consensus practice is to screen patients with active SLE for proteinuria and hematuria at least every three months, even in the absence of new symptoms, to intercept renal involvement before irreversible scarring occurs [38]. Despite their ubiquity, proteinuria and creatinine are blunt tools. Both may lag behind immunologic changes and, when abnormal, can reflect longstanding injury rather than contemporaneous inflammatory activity. This limitation has accelerated interest in more responsive urinary biomarkers that mirror intrarenal immunopathology. Among these, urinary soluble CD163—a cleaved product of the hemoglobin–haptoglobin scavenger receptor on activated macrophages—has emerged as a particularly promising indicator. Multiple studies demonstrate that uCD163 levels track closely with histologic activity and clinical flares in lupus nephritis; importantly, declines in uCD163 frequently precede improvements in proteinuria and serum creatinine, suggesting it may function as an "early warning" signal of therapeutic response [38][39]. Moreover, receiver operating characteristic analyses indicate that uCD163 outperforms traditional serologies (anti-dsDNA, complement) for flare discrimination in some cohorts, supporting its potential role in risk stratification and treatment tailoring across inflammatory renal diseases [37][39]. While standardization of assays and threshold values remains an active area of research, integrating uCD163 into the laboratory panel can refine decision-making, particularly when conventional metrics are equivocal. Additional laboratory information contextualizes renal risk and complications. Persistent hypoalbuminemia reflects either ongoing nephrotic loss or malnutrition and portends edema, hyperlipidemia, and thrombotic vulnerability, whereas active urinary sediment—dysmorphic red cells, leukocytes, and casts—supports ongoing glomerular inflammation even when proteinuria appears modest [37]. Serial linkage between serologic activity (rising anti-dsDNA, falling complement) and urinary abnormalities can guide the timing of biopsy and intensity of immunosuppression, while normalization of complement and antibody titers, coupled with improving urine indices, generally signifies remission trajectories, though histologic confirmation is sometimes needed to validate true quiescence [38][39].

Radiographic

Imaging complements laboratory testing by excluding structural mimics of medical renal disease. A bilateral renal ultrasound is recommended to evaluate kidney size and echogenicity and to rule out hydronephrosis or obstructive uropathy that could account for reductions in glomerular filtration rate. Although ultrasound cannot diagnose lupus nephritis or distinguish among its classes, the identification of small, highly echogenic kidneys may suggest advanced chronicity, informing both prognosis and the risk–benefit calculus of invasive diagnostics or aggressive immunosuppression [37]. In practice, ultrasound is often performed prior to renal biopsy to delineate anatomy, select the safer kidney for sampling, and screen for unexpected obstructive processes that would redirect management.

Biopsy

Renal biopsy remains the gold standard for diagnosing lupus nephritis and for staging disease activity and chronicity. Histologic classification according to the World Health Organization and International Society of Nephrology/Renal Pathology Society frameworks defines the distribution and intensity of immune complex deposition, endocapillary proliferation, necrosis, crescents, and scarring; these features carry distinct prognostic implications and guide the choice and duration of immunosuppressive regimens [30][33]. Although clinicians occasionally infer the presence of lupus nephritis from clinical and serologic data alone, biopsy yields irreplaceable information—particularly the activity and chronicity indices—that cannot be reliably deduced from creatinine, proteinuria, or complement levels. Consequently, biopsy should be pursued whenever its results are likely to alter management, such as clarifying proliferative versus membranous patterns, quantifying active lesions that warrant induction therapy, or documenting chronic, irreversible change that would temper expectations for recovery [40]. Biopsy is not without risk. Complications are more frequent in patients with thrombocytopenia, coagulopathy, or markedly shrunken kidneys, and in these situations clinicians may initiate empiric therapy without tissue confirmation, especially if other severe SLE manifestations (e.g., central nervous system or hematologic involvement) already necessitate cytotoxic agents such as cyclophosphamide [41]. Even when safely obtained, sampling error and interpretive variability must be acknowledged: focal lesions can be missed in small cores, and interobserver differences exist in scoring crescents, necrosis, and interstitial disease. Nevertheless, interpretive consistency is greater at high-volume centers, where pathologists with dedicated expertise in medical renal biopsies provide more reproducible readings across serial specimens [41][42]. For these reasons, biopsy interpretation should always be integrated with clinical presentation, serology, and urinary indices to avoid over- or undertreatment.

A crucial insight from contemporary cohorts is the frequent discordance between clinical and histologic responses. Many patients who meet clinical remission criteria—serum creatinine near baseline and proteinuria below 500 mg/day or reduced by at least half—still harbor histologically active nephritis on repeat biopsy at 6 to 8 months, with activity indices significantly above zero [40][42]. This occult activity correlates with future renal flares and inferior long-term outcomes, implying that reliance on proteinuria and creatinine alone may permit smoldering inflammation to progress. Conversely, some patients cannot meet standard clinical remission thresholds due to fixed chronic damage; in such cases, a repeat biopsy demonstrating an activity index near zero can justify tapering or discontinuing immunosuppression despite residual proteinuria attributable to scarring rather than ongoing immune injury [27][43]. Thus, judicious use of protocolized or indication-driven repeat biopsy can tailor therapy more precisely than clinical metrics alone. The temporal kinetics of histologic healing are heterogeneous. Complete histologic remission—defined by the absence of active lesions—can lag behind clinical improvement by months and, in some patients, by years; reports document time frames stretching up to a decade before full histologic quiescence is achieved, even under well-controlled clinical conditions [27]. Recognizing this lag prevents premature cessation of therapy that might otherwise invite relapse and acknowledges that proteinuria reduction often reflects both immunologic control and slow structural repair of the filtration barrier. The converse is equally important: persistent histologic activity in the face of improving proteinuria should prompt consideration of intensifying or prolonging immunosuppression to forestall future flares and cumulative scarring [40][41].

Prospective data support a biopsy-guided de-escalation strategy. In a trial from Argentina, patients with proliferative lupus nephritis underwent planned withdrawal of immunosuppression only if a repeat biopsy showed an activity index of zero. Over a median follow-up of eight years, subsequent lupus flares occurred in 9.2% of participants—a rate substantially lower than those reported in similar cohorts managed without biopsy confirmation, where flare frequencies ranged from 1.7- to 68-fold higher depending on study design and population [44]. These findings suggest that histologic verification of quiescence provides a safer foundation for tapering therapy than clinical criteria alone, potentially reducing both relapse risk and cumulative drug toxicity. Although generalizability requires confirmation in broader, multiethnic cohorts, the study offers a pragmatic template for integrating repeat biopsy into remission maintenance algorithms. Taken together, a modern evaluation framework for lupus nephritis weaves laboratory surveillance, targeted imaging, and judicious biopsy into a coherent strategy. Regular three-month screening for proteinuria and hematuria during active SLE identifies renal involvement early; serologic trends in complement and anti-dsDNA titers contextualize risk; and emerging biomarkers like urinary soluble CD163 refine detection of subclinical activity and capture response earlier than conventional metrics [37][38][39]. Ultrasound ensures that structural confounders are excluded and that biopsy can be performed safely. Most importantly, biopsy provides the histologic specificity—class, activity, chronicity—required to personalize immunosuppression, to calibrate expectations for recovery, and, when repeated in selected scenarios, to guide de-escalation with a lower probability of relapse. By integrating these elements, clinicians can move beyond reactive care toward proactive, tissue-informed decision-making that maximizes kidney preservation while minimizing unnecessary exposure to immunosuppressive risk [41][42][44].

Treatment / Management

The management of lupus nephritis is anchored in histopathological class and unfolds across two complementary phases—induction to quell active inflammation and maintenance to consolidate remission and prevent relapse—while simultaneously addressing cardiovascular and renal risk factors that accelerate chronic kidney disease (CKD) progression. Across virtually all classes, background therapy with hydroxychloroquine is recommended at baseline unless contraindicated, coupled with regular ophthalmologic monitoring to mitigate the risk of retinal toxicity. Randomized and observational data indicate that patients receiving hydroxychloroquine experience fewer flares than those not treated, supporting its foundational role in systemic lupus erythematosus (SLE) and renal disease management [45][46][47]. For classes I and II lupus nephritis, careful surveillance often suffices, especially when proteinuria remains below 500 mg/day; by contrast, proliferative phenotypes (classes III and IV) generally require timely immunosuppressive induction followed by structured maintenance, and extensively scarred kidneys in class VI necessitate a shift toward renal replacement strategies rather than further cytotoxic escalation. Notably, the presence of active lesions predicts better treatment responsiveness than advanced chronic damage, an observation that should guide both patient counseling and therapeutic intensity (B3). Equally critical is rigorous modification of modifiable risk factors that potentiate CKD and end-stage renal disease (ESRD) in lupus nephritis. Dyslipidemia should be treated with statins given the heightened atherosclerotic risk in SLE and CKD, which together amplify cardiovascular morbidity and mortality. Blood pressure control, preferentially with renin–angiotensin system blockade using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, is recommended when proteinuria or hypertension is present, both to reduce intraglomerular pressure and to lower proteinuria. Adjunctive nutritional and nutraceutical strategies have reported benefits on inflammatory biomarkers and endothelial function: vitamin D and E repletion and omega-3 fatty acids have been associated with improvements in systemic inflammation and fatigue in SLE, and small studies of curcumin suggest anti-inflammatory, antioxidant, and anti-proteinuric effects in lupus nephritis, though standardization and confirmatory trials remain areas of active investigation [15][48]. These supportive measures complement, rather than replace, disease-modifying immunosuppression.

The contemporary treatment paradigm distinguishes an induction phase—aimed at achieving renal response as efficiently and safely as possible—from a maintenance phase designed to reduce relapse risk with lower-intensity regimens over a prolonged period. Guideline bodies including the European Alliance of Associations for Rheumatology (EULAR), the European Renal Association (ERA), and Kidney Disease: Improving Global Outcomes (KDIGO) recommend maintenance therapy following initial response with low-dose mycophenolate mofetil (MMF) or azathioprine, with or without low-dose glucocorticoids (<7.5 mg prednisone equivalent), for at least three years once stable clinical remission is achieved (KDIGO permits a shorter minimum, 12 months, in sustained remission) [45]. Throughout induction, prophylaxis against Pneumocystis pneumonia should be provided, given the cumulative immunosuppressive burden; longer-term glucocorticoid exposure also necessitates bone-protective strategies, including calcium and vitamin D supplementation and a baseline dual-energy x-ray absorptiometry scan to track bone mineral density [49][50]. For proliferative lupus nephritis (classes III and IV), the 2019 EULAR recommendations support two primary induction options: MMF (2–3 g/day or equivalent mycophenolic acid) or cyclophosphamide (e.g., 500 mg intravenously for six biweekly doses), each combined with a short course of high-dose glucocorticoids (typically three days of intravenous pulses followed by a taper to the lowest effective oral dose). Notably, pairing cyclophosphamide with pulse steroids at each dose is associated with improved outcomes and the opportunity to curtail cumulative oral steroid exposure in classes III, IV, and V disease, reflecting an evolving emphasis on steroid minimization where feasible [45][51]. In patients presenting with nephrotic-range proteinuria or with adverse prognostic features, either MMF in combination with a calcineurin inhibitor or higher-dose cyclophosphamide may be considered as alternative induction paths; in responders, the median time to complete remission during induction is approximately 4.3 months, with a typical range of two to six months, a timeframe that can help set expectations for patients and clinicians [40].

Agent selection should be individualized to clinical context and comorbidity. Cyclophosphamide remains the preferred option when SLE manifests with life-threatening organ involvement (e.g., pulmonary hemorrhage) or rapidly progressive glomerulonephritis, where its potency and experience base are advantageous [18]. However, multiple comparative studies indicate that MMF is superior to cyclophosphamide for induction in proliferative lupus nephritis among Black, Hispanic, and Chinese populations, and mechanistic work suggests MMF exerts particular effects on dendritic cells that may underpin this benefit [18][52][53][9] (A1). Where intolerance or contraindications to these agents exist, or when therapeutic goals are not met with standard regimens, sirolimus (an mTOR inhibitor), tacrolimus, cyclosporine, or methotrexate may be employed in selected patients; evidence from the Chinese Systemic Lupus Erythematosus Treatment and Research Group suggests sirolimus can outperform tacrolimus in reducing glucocorticoid exposure and improving serologic profiles, highlighting a potential steroid-sparing role in difficult cases [9][54]. Once an initial renal response is achieved, therapy transitions to maintenance. If improvement is documented by six months, clinicians commonly de-escalate to lower doses of MMF or switch to azathioprine; randomized data support MMF as superior to azathioprine for maintenance in preventing relapse and preserving renal function, which has elevated MMF to a preferred maintenance agent in many protocols (A1) [55][56]. Nevertheless, azathioprine remains an important option, particularly for patients planning pregnancy or for those with MMF intolerance, and the final choice should incorporate patient preference, reproductive plans, prior adverse effects, and adherence considerations. During maintenance, persistent attention to tight blood pressure control, lipid management, and proteinuria reduction is essential, because cardiometabolic risk tracks closely with renal outcomes in lupus nephritis [45][48].

Reassessment is necessary when induction fails to achieve an adequate renal response by approximately six months. At that juncture, switching to the alternative induction agent (e.g., MMF ↔ cyclophosphamide) is common practice, and many clinicians consider B-cell–directed therapy. Rituximab is widely used in refractory lupus nephritis due to its accepted safety profile and biologic plausibility; however, the LUNAR trial did not demonstrate a statistically significant improvement when rituximab was added to standard MMF-based therapy in active proliferative disease, though numerical trends favored rituximab and it remains a pragmatic option in real-world refractory scenarios [45][18][57]. When contemplating such changes, a repeat kidney biopsy can be invaluable in discriminating against ongoing activity from entrenched chronicity; escalation of immunosuppression is unlikely to reverse fixed scarring, whereas persistent active lesions justify intensified therapy despite only partial clinical responses [40]. Class-specific nuances merit emphasis. In membranous lupus nephritis (class V), where nephrotic physiology dominates, therapeutic regimens often combine anti-proteinuric strategies with immunomodulation tailored to proteinuria severity and concomitant proliferative lesions. When class V coexists with class III or IV features, clinicians typically treat according to proliferative protocols (MMF or cyclophosphamide with glucocorticoids), because the inflammatory component most strongly dictates renal prognosis [45][51]. In contrast, advanced sclerosing lupus nephritis (class VI), defined by ≥90% globally sclerosed glomeruli, signals irreversible damage; here, the focus shifts to preparing for renal replacement therapy, managing complications of advanced CKD, and avoiding immunosuppression that is unlikely to improve outcomes. This pivot underscores the axiom that “activity responds; chronicity does not,” a principle reinforced by the prognostic weight of chronicity indices on biopsy [49][50].

Glucocorticoid stewardship threads through all phases of care. While high-dose steroids hasten control of glomerular inflammation, cumulative exposure drives metabolic, skeletal, and infectious complications. Therefore, protocols increasingly employ rapid steroid tapers and adjunctive agents to achieve steroid-sparing control. Prophylaxis against Pneumocystis pneumonia during induction, vaccination updates when immunologically appropriate, bone health surveillance with dual-energy x-ray absorptiometry, and lifestyle interventions (exercise, nutrition, smoking cessation) should be standardized components of care to mitigate iatrogenic harm [49][50]. In parallel, careful laboratory and clinical monitoring—quarterly in active phases—allows timely detection of subclinical flares and adjustment of therapy before overt deterioration, with particular attention to proteinuria trajectories, complement and anti-dsDNA trends, and emerging biomarkers such as urinary soluble CD163, which may signal response or flare earlier than conventional measures [37][38][39]. Therapeutic decision-making should also account for heterogeneity across populations. Evidence supporting MMF’s superior induction performance in Black, Hispanic, and Chinese cohorts highlights the value of tailoring regimens to ancestry-associated risk profiles, access-to-care variables, and comorbidity patterns [18][52][53]. Social determinants of health—adherence barriers, insurance coverage, and proximity to subspecialty care—often shape outcomes as emphatically as pharmacology; thus, clear education on medication goals and side effects, shared decision-making regarding risks and benefits, and close follow-up are essential adjuncts to any pharmacologic plan [45][48]. Finally, long-term strategy requires realistic goal-setting that integrates histology, clinical response, and patient priorities. The median two-to-six-month window for induction response provides a practical benchmark, but some patients require longer to achieve proteinuria reductions commensurate with structural healing of the glomerular filtration barrier. Others, constrained by chronic scarring, may never fully normalize creatinine or proteinuria; in these cases, if repeat biopsy demonstrates an activity index near zero, cautious de-escalation of immunosuppression may be justified to reduce toxicity without materially increasing relapse risk [27][40]. The overarching objective is durable renal preservation with the fewest complications—an outcome most likely when therapy is biopsy-informed, steroid-sparing, risk-factor–focused and adapted to the individual’s clinical course and life context [41][45][56][57].

Induction Therapy for Class V Lupus Nephritis

The therapeutic approach to class V (membranous) lupus nephritis aims to control immune-mediated podocyte injury, reduce proteinuria, and forestall chronic scarring while minimizing treatment toxicity. Hydroxychloroquine should be co-prescribed unless contraindicated, given its broad flare-preventive effects and favorable safety when appropriately monitored with periodic ophthalmologic examinations [7]. In patients whose proteinuria exceeds 1 g/day, immunosuppressive therapy is generally warranted in addition to hydroxychloroquine, as persistent nephrotic-range protein loss accelerates tubulointerstitial damage, thrombosis risk, and cardiovascular morbidity [7]. The standard initial regimen consists of mycophenolate mofetil (MMF) plus prednisone for approximately six months, with the glucocorticoid course front-loaded (often a brief pulse followed by a structured taper) to suppress active inflammation rapidly while limiting cumulative steroid exposure [30]. When clinical improvement—typically defined by falling proteinuria, stabilization or improvement of serum creatinine, and quiescent urinary sediment—is achieved, therapy transitions to maintenance with a reduced MMF dose or azathioprine, selected on the basis of tolerability, comorbidities, reproductive plans, and adherence considerations [30]. If proteinuria and serologic/urinary indices fail to improve adequately by about six months, intensification is appropriate. One evidence-based option is cyclophosphamide combined with pulse-dose glucocorticoids for an additional six months, prioritizing regimens that allow steroid minimization while delivering sufficient cytotoxic potency to reverse ongoing immune activity [30]. In patients with membranous features plus proliferative changes (class III or IV) on biopsy, management should align with the class III/IV induction protocol, because the proliferative component most strongly determines renal prognosis and requires more assertive immunosuppression [30]. Beyond MMF and cyclophosphamide, calcineurin inhibitors (CNIs)—tacrolimus, cyclosporine, and the newer voclosporin—as well as azathioprine with steroids can be considered in selected cases to enhance anti-proteinuric effects or address drug intolerance, always balancing efficacy with risks such as nephrotoxicity and infectious complications [7]. The strategic objective in class V disease is a sustained reduction of proteinuria to sub-nephrotic or near-complete remission, recognizing that structural repair of the filtration barrier lags behind immunologic control. Consequently, close monitoring every one to three months during induction—tracking proteinuria, albumin, creatinine, complements, and anti-dsDNA—guides tapering, switching, or escalation. Concomitant renin–angiotensin system blockade, dietary sodium moderation, lipid control, and thrombosis prophylaxis in high-risk nephrotic states are essential co-therapies that improve outcomes and reduce non-immune drivers of progression [7][30].

Renal Replacement Therapy

A proportion of patients with lupus nephritis progress to end-stage renal disease (ESRD) despite contemporary therapy. Reassuringly, once on dialysis, outcomes are broadly comparable to those of patients whose ESRD stems from non-lupus etiologies, reflecting advances in both dialysis care and systemic lupus management [7]. Transplant candidacy should be discussed early—typically when the glomerular filtration rate falls below 20 mL/min—to allow timely evaluation and listing, as in other ESRD populations [7]. Historical practice favored prolonged hemodialysis to ensure immunologic quiescence before transplantation; however, contemporary data do not support mandatory waiting periods, and preemptive transplantation is associated with better allograft function without higher rates of recurrent lupus in the graft [58]. The risk of recurrent lupus pathology in the allograft is relatively low—estimated at 2% to 11% at a median four-year follow-up—and overall graft survival approximates that seen in non-lupus transplant cohorts [7][58]. These observations reinforce an individualized, forward-leaning transplant strategy, emphasizing disease control rather than arbitrary dialysis duration.

Pregnancy

Because SLE and lupus nephritis predominantly affect women of childbearing age, fertility preservation, pregnancy timing, and medication safety are central to care. Rituximab is often preferred over cyclophosphamide in women prioritizing fertility preservation, given cyclophosphamide's gonadotoxic potential [9][18]. Prior to conception, women should be tested for antiphospholipid antibodies—lupus anticoagulant, anticardiolipin, and β-2 glycoprotein I—to stratify risks of thrombosis, preeclampsia, and pregnancy loss. Screening for anti-Ro/SSA and anti-La/SSB is recommended due to the association with congenital heart block, enabling plans for fetal echocardiographic surveillance when indicated [59]. Ideally, patients should achieve clinical remission for ≥6 months before attempting pregnancy, as active nephritis at conception portends worse maternal and fetal outcomes [18]. During pregnancy, glucocorticoids (prednisone, dexamethasone, or betamethasone) remain first-line for controlling active renal and systemic disease, while azathioprine can be added as a steroid-sparing agent when higher doses would otherwise be required [18]. Hydroxychloroquine should be continued, as it reduces lupus activity and flare risk and is associated with improved pregnancy outcomes. Belimumab can be used until the second trimester in selected situations, though multidisciplinary risk–benefit discussion is warranted [9][18]. To reduce preeclampsia and thrombotic risk, low-dose aspirin is typically initiated around 12 weeks' gestation unless contraindicated, complementing close obstetric–rheumatology–nephrology collaboration throughout gestation [18].

Antiphospholipid Syndrome

In patients with SLE who test positive for antiphospholipid antibodies, thrombosis risk is substantially elevated. Hydroxychloroquine is recommended for its thromboprotective effects, and low-dose aspirin may be considered—particularly in those with additional risk factors—to mitigate arterial and venous events [60]. Lupus anticoagulant positivity confers a marked increase in arterial thrombosis, necessitating a conservative approach to exogenous estrogen. Specifically, combined oral contraceptives, patches, and rings should be avoided in patients with SLE and antiphospholipid antibodies due to the heightened thrombotic risk [61][62]. Importantly, antiphospholipid positivity in candidates for transplantation is associated with higher renal allograft loss, so careful thrombosis prevention and perioperative planning are integral to the transplant workup (B2) [61][62].

New Therapies

The last several years have ushered in multitargeted strategies that layer biologic and small-molecule agents atop conventional regimens, enabling more personalized treatment calibrated to serologic activity, ancestry-related risks, and biopsy features. Two agents have regulatory approval specifically for lupus nephritis: belimumab and voclosporin. Belimumab, a soluble BAFF (B-cell activating factor) antibody approved for SLE in 2011, received approval in 2020 for induction therapy in lupus nephritis in addition to standard MMF/cyclophosphamide/steroid protocols. The BLISS-LN trial demonstrated improved renal outcomes with belimumab add-on, supporting its incorporation into induction for appropriate patients [46][63] (A1). A complementary mechanistic narrative posits that BAFF surges after B-cell depletion may fuel disease recrudescence; in the BEAT LUPUS trial, belimumab after rituximab lowered anti-dsDNA titers and reduced nephritis flares versus placebo, reinforcing sequential targeting of B-cell survival signals in refractory disease [64]. Clinically, belimumab seems particularly helpful in patients with high serologic activity and prominent cutaneous or musculoskeletal involvement, without the nephrotoxicity concerns that can limit CNI use [61]. Voclosporin, a next-generation calcineurin inhibitor, suppresses IL-2–dependent T-cell activation and stabilizes podocyte cytoskeleton dynamics, thereby exerting both immunologic and anti-proteinuric effects. Compared with tacrolimus or cyclosporine, voclosporin is more potent and pharmacokinetically stable, obviating routine drug-level monitoring in most patients [65][66]. It can be particularly effective in those with proteinuria >3.0 g/day, in whom rapid reductions in urinary protein are desirable; by contrast, belimumab is less nephrotoxic and can be used in the setting of impaired renal function [67][68]. Notably, both agents have been associated with faster glucocorticoid tapering, an increasingly prioritized goal to limit steroid-related complications [18].

Phase-3 Trials

A robust pipeline of phase-3 candidates suggests an evolving standard of care that will further individualize therapy. Anifrolumab, an interferon-α receptor antagonist, interrupts the type-I IFN axis that primes dendritic cells, B cells, T cells, and parenchymal targets; it improved key disease parameters when added to standard therapy and was approved in 2021 for moderate-to-severe SLE, with accumulating experience in renal subsets [9]. Atacicept, a fusion protein comprising the TACI receptor linked to IgG Fc, neutralizes BAFF and APRIL simultaneously and may yield broader B-cell modulation than BAFF-only strategies; telitacicept employs a similar dual-ligand approach. Additional B-cell–directed antibodies—including obinutuzumab, ocrelizumab, and epratuzumab (targeting CD20 and CD22)—are under investigation to refine depletion depth and durability [9]. Ianalumab, a BAFF-receptor–targeting monoclonal with dual actions, has shown promise in related autoimmunity (e.g., Sjögren syndrome), offering a potential path to durable B-cell pathway control. Beyond B cells, deucravacitinib, a selective TYK2 inhibitor, modulates type-I IFN–associated gene expression and downstream cytokine networks with greater specificity than first-generation JAK inhibitors, aiming for efficacy with reduced off-target toxicity. In parallel, SGLT2 inhibitors—now foundational in diabetic and non-diabetic CKD—reduce proteinuria and mortality across renal diseases and, in a large SLE cohort, were associated with a lower risk of developing lupus nephritis, suggesting both preventive and adjunctive therapeutic roles in selected patients [18][46]. Finally, povetacicept, a next-generation dual BAFF/APRIL antagonist, has entered early human studies with encouraging tolerability and serologic signals—namely, reductions in targeted antibody pools—spurring interest in antibody-mediated renal autoimmunity, including lupus nephritis and IgA nephropathy [69] (A1). Together, these advances mark a transition from one-size-fits-all regimens toward algorithmic, biomarker-informed care. For class V lupus nephritis, that means combining hydroxychloroquine, MMF-based induction (or appropriate alternatives), meticulous risk-factor control, and judicious biologic or CNI add-ons to meet proteinuria and serologic goals while curbing steroid exposure. As phase-3 data mature and dual-pathway agents enter practice, the capacity to match mechanism to phenotype—and to a patient's pregnancy plans, ancestry-related risks, and biopsy-specific activity/chronicity—should further improve renal preservation and quality of life in this challenging, heterogeneous disease [7][30][58][61][63][67].

Prognosis

Prognosis in lupus nephritis is tightly linked to histopathologic class and the balance between active inflammation and chronic scarring. Classes I (minimal mesangial) and II (mesangial proliferative) generally portend favorable long-term renal preservation under vigilant surveillance and risk-factor control. Progression to proliferative classes worsens outlook: class III carries a poorer prognosis due to focal but often aggressive lesions, and class IV has the gravest trajectory given diffuse endocapillary proliferation, crescents, and high relapse rates without timely induction and sustained maintenance therapy. Early initiation of evidence-based treatment is crucial; therapeutic delay permits accrual of irreversible chronicity that blunts response and increases the likelihood of end-stage renal disease. Over the past four decades, outcomes have markedly improved. In the 1950s, five-year survival was near zero for lupus nephritis; with the advent of glucocorticoids and immunosuppressants—particularly mycophenolate mofetil and cyclophosphamide—contemporary five-, ten-, and twenty-year survival rates for biopsy-proven disease have risen to approximately 94%, 86%, and 71%, respectively [29]. Mortality among patients who progress to ESRD has also declined substantially. From 1995–1999 to 2010–2014, mortality per 100 patient-years fell from 11.1 to 6.7, driven by reductions in deaths from cardiovascular disease and infection—44% and 63% decreases, respectively—reflecting better cardiovascular risk management, vaccination, infection prophylaxis, and dialysis and transplant care [29][70]. Even so, cardiovascular disease and serious infection remain the dominant causes of death, emphasizing the need for stringent blood pressure and lipid control, judicious immunosuppression, vaccination, and early referral for renal replacement therapy or transplantation when indicated.

Enhancing Healthcare Team Outcomes:

Optimal outcomes in lupus nephritis depend on coordinated, role-specific excellence across the care continuum. Nurses are frontline integrators: they perform blood pressure surveillance, edema assessments, and medication reconciliation at every encounter; teach self-monitoring of weight, home blood pressure, and symptom diaries; reinforce steroid-sparing strategies; triage red-flag symptoms (sudden dyspnea, chest pain, marked oliguria); and coordinate vaccination and bone-health protocols. Nurse-led telephone or telehealth check-ins between visits can detect early relapse signals and address adherence barriers, reducing emergency utilization. Family medicine physicians anchor longitudinal, whole-person care—screening quarterly urinalyses in active SLE, managing hypertension with ACE inhibitors/ARBs, titrating statins, addressing diabetes or obesity, and orchestrating cancer screening and contraception choices that respect antiphospholipid status. They also time preconception counseling, initiate low-dose aspirin in pregnancy when indicated, and expedite referral to rheumatology and nephrology for evolving renal signs. The laboratory team underpins precision monitoring: standardized measurement of protein–creatinine ratios, timely complement (C3/C4) and anti-dsDNA trends, and validated platforms for emerging biomarkers such as urinary soluble CD163 improve detection of subclinical activity and gauge treatment response. Close lab–clinician feedback loops shorten decision cycles when results change rapidly. Medical records professionals ensure interoperability and completeness of the kidney care dataset: problem lists reflect biopsy class and activity/chronicity indices; medication lists flag teratogens and cumulative cyclophosphamide exposure; dashboards trend proteinuria, creatinine, complements, blood pressure, and vaccinations; and structured biopsy synopses are readily accessible across specialties. Robust documentation supports quality metrics (e.g., ACEi/ARB use with proteinuria), enables population health outreach for missed monitoring, and enhances safety by surfacing drug–disease interactions. By aligning nursing vigilance, primary-care stewardship, laboratory rigor, and high-fidelity information management, teams create a proactive learning system that detects flares earlier, individualizes therapy, and measurably improves renal and cardiovascular outcomes in lupus nephritis.

Conclusion:

In conclusion, lupus nephritis remains a severe and potentially life-threatening complication of systemic lupus erythematosus, driven by a complex interplay of genetic, environmental, and immunologic factors. Its management has evolved significantly, moving from a one-size-fits-all approach to a more personalized, precision-based strategy. The cornerstone of effective care is a timely renal biopsy, which provides critical prognostic information through histopathological classification and scoring of activity and chronicity. This guides the strategic use of induction and maintenance immunosuppressive therapies, now enhanced by novel biologic agents like belimumab and voclosporin, which offer improved efficacy and steroid-sparing potential. Ultimately, optimizing long-term outcomes requires an integrated, interdisciplinary healthcare model. Success hinges on the seamless collaboration of rheumatologists, nephrologists, nurses, primary care physicians, and laboratory professionals. This team ensures vigilant monitoring for early signs of renal involvement, prompt diagnosis, tailored treatment regimens, aggressive management of cardiovascular risk factors, and comprehensive patient education. Such a coordinated effort is essential to suppress disease activity, prevent flares and progressive chronic kidney damage, reduce treatment-related complications, and improve survival. Through this collaborative framework, the goal of preserving renal function and enhancing the quality of life for patients with lupus nephritis becomes an achievable reality.

References:

1. Liu G, Wang H, Le J, Lan L, Xu Y, Yang Y, Chen J, Han F. Early-stage predictors for treatment responses in patients with active lupus nephritis. Lupus. 2019 Mar:28(3):283-289. doi: 10.1177/0961203319826703.
2. Slight-Webb S, Guthridge JM, Chakravarty EF, Chen H, Lu R, Macwana S, Bean K, Maecker HT, Utz PJ, James JA. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients. JCI insight. 2019 Jan 24:4(2):. doi: 10.1172/jci.insight.124575.
3. Wang ZR, Ren LM, Li R, Guan X, Han QM, Liu ML, Shao M, Zhang X, Chen S, Li ZG. [Analysis of 20-year survival rate and prognostic indicators of systemic lupus erythematosus]. Zhonghua yi xue za zhi. 2019 Jan 15:99(3):178-182. doi: 10.3760/cma.j.issn.0376-2491.2019.03.005.
4. Wilson HR, Medjeral-Thomas NR, Gilmore AC, Trivedi P, Seyb K, Farzaneh-Far R, Gunnarsson I, Zickert A, Cairns TD, Lightstone L, Cook HT, Pickering MC. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. Kidney international. 2019 Mar:95(3):655-665. doi: 10.1016/j.kint.2018.09.027.
5. Tamirou F, Houssiau FA. Management of Lupus Nephritis. Journal of clinical medicine. 2021 Feb 9:10(4):. doi: 10.3390/jcm10040670.
6. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus. 2008 May:17(5):426-30. doi: 10.1177/0961203308090029.
7. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2020 Aug:76(2):265-281. doi: 10.1053/j.ajkd.2019.10.017.
8. Iwamoto T, Niewold TB. Genetics of human lupus nephritis. Clinical immunology (Orlando, Fla.). 2017 Dec:185():32-39. doi: 10.1016/j.clim.2016.09.012.
9. Su X, Yu H, Lei Q, Chen X, Tong Y, Zhang Z, Yang W, Guo Y, Lin L. Systemic lupus erythematosus: pathogenesis and targeted therapy. Molecular biomedicine. 2024 Oct 30:5(1):54. doi: 10.1186/s43556-024-00217-8.

10. Munroe ME, James JA. Genetics of Lupus Nephritis: Clinical Implications. Seminars in nephrology. 2015 Sep:35(5):396-409. doi: 10.1016/j.semnephrol.2015.08.002.
11. Pan Q, Guo F, Huang Y, Li A, Chen S, Chen J, Liu HF, Pan Q. Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies. Frontiers in immunology. 2021:12():799788. doi: 10.3389/fimmu.2021.799788.
12. Skopelja-Gardner S, Tai J, Sun X, Tanaka L, Kuchenbecker JA, Snyder JM, Kubes P, Mustelin T, Elkon KB. Acute skin exposure to ultraviolet light triggers neutrophil-mediated kidney inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2021 Jan 19:118(3):. doi: 10.1073/pnas.2019097118.
13. Bai H, Jiang L, Li T, Liu C, Zuo X, Liu Y, Hu S, Sun L, Zhang M, Lin J, Xiao W, Wang Q, Zhao D, Wu H, Kong X, Gao W, Hou W, Seong M, Zhang Y, Chen F, Chen S, Wu X, Bao C, Wang L, Xu H. Acute effects of air pollution on lupus nephritis in patients with systemic lupus erythematosus: A multicenter panel study in China. Environmental research. 2021 Apr:195():110875. doi: 10.1016/j.envres.2021.110875.
14. López P, Sánchez B, Margolles A, Suárez A. Intestinal dysbiosis in systemic lupus erythematosus: cause or consequence? Current opinion in rheumatology. 2016 Sep:28(5):515-22. doi: 10.1097/BOR.0000000000000309.
15. Monticolo M, Mucha K, Foroncewicz B. Lupus Nephritis and Dysbiosis. Biomedicines. 2023 Apr 13:11(4):. doi: 10.3390/biomedicines11041165.
16. Azzouz D, Omarbekova A, Heguy A, Schwudke D, Gisch N, Rovin BH, Caricchio R, Buyon JP, Alekseyenko AV, Silverman GJ. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Annals of the rheumatic diseases. 2019 Jul:78(7):947-956. doi: 10.1136/annrheumdis-2018-214856.
17. Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V. Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story. Viruses. 2021 Feb 11:13(2):. doi: 10.3390/v13020277.
18. Roveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, Francese A, Maconi AG, Quaglia M. Lupus Nephritis from Pathogenesis to New Therapies: An Update. International journal of molecular sciences. 2024 Aug 18:25(16):. doi: 10.3390/ijms25168981.
19. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging mechanisms. Autoimmunity reviews. 2008 Feb:7(4):317-21. doi: 10.1016/j.autrev.2007.12.001.
20. Strizzi CT, Ambrogio M, Zanoni F, Bonerba B, Bracaccia ME, Grandaliano G, Pesce F. Epitope Spreading in Immune-Mediated Glomerulonephritis: The Expanding Target. International journal of molecular sciences. 2024 Oct 16:25(20):. doi: 10.3390/ijms252011096.
21. Bruschi M, Angeletti A, Prunotto M, Meroni PL, Ghiggeri GM, Zeus consortium, Moroni G, Sinico RA, Franceschini F, Fredi M, Vaglio A, Cavalli A, Scapozza L, Patel JJ, Tan JC, Lo KC, Cavagna L, Petretto A, Pratesi F, Migliorini P, Locatelli F, Pazzola G, Pesce G, Giannese D, Manfredi A, Ramirez GA, Esposito P, Murdaca G, Negrini S, Bui F, Trezzi B, Emmi G, Cavazzana I, Binda V, Fenaroli P, Pisan I, Montecucco C, Santoro D, Scolari F, Mescia F, Volpi S, Mosca M, Tincani A, Ravelli A, Murtas C, Candiano G, Caridi G, La Porta E, Verrina E. A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence. Autoimmunity reviews. 2024 May:23(5):103535. doi: 10.1016/j.autrev.2024.103535.
22. Zervopoulou E, Grigoriou M, Doumas SA, Yiannakou D, Pavlidis P, Gasparoni G, Walter J, Filia A, Gakiopoulou H, Banos A, Mitroulis I, Boumpas DT. Enhanced medullary and extramedullary granulopoiesis sustain the inflammatory response in lupus nephritis. Lupus science & medicine. 2024 Mar 11:11(1):. doi: 10.1136/lupus-2023-001110.
23. Hong S, Healy H, Kassianos AJ. The Emerging Role of Renal Tubular Epithelial Cells in the Immunological Pathophysiology of Lupus Nephritis. Frontiers in immunology. 2020:11():578952. doi: 10.3389/fimmu.2020.578952.
24. Luo M, Lıu J, Yuan Y, Chen Y, Yuan G. The role of vitamin D-synthesizing enzyme CYP27B1 in systemic lupus erythematosus. Turkish journal of medical sciences. 2022 Aug:52(4):98
25. Kaneko M, Jackson SW. Recent advances in immunotherapies for lupus nephritis. Pediatric nephrology (Berlin, Germany). 2023 Apr:38(4):1001-1012. doi: 10.1007/s00467-022-05670-7.
26. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis and rheumatism. 2008 Feb:58(2):556-62. doi: 10.1002/art.23204.
27. Rodriguez-Ramirez S, Wiegley N, Mejia-Vilet JM. Kidney Biopsy in Management of Lupus Nephritis: A Case-Based Narrative Review. Kidney medicine. 2024 Feb:6(2):100772. doi: 10.1016/j.xkme.2023.100772.
28. Yap DY, Chan TM. Lupus Nephritis in Asia: Clinical Features and Management. Kidney

diseases (Basel, Switzerland). 2015 Sep:1(2):100-9. doi: 10.1159/000430458.
29. Wang H, Ren YL, Chang J, Gu L, Sun LY. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Archives of rheumatology. 2018 Mar:33(1):17-25. doi: 10.5606/ArchRheumatol.2017.6127
30. Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford, England). 2020 Dec 5:59(Suppl5):v39-v51. doi: 10.1093/rheumatology/keaa381.
31. Hashmi AA, Ali J, Rahman M, Taseer AR, Kumar J, Irfan M. Spectrum of Morphologic Features of Lupus Nephritis According to Nephrology/Renal Pathology Society (ISN/RPS) Classification. Cureus. 2020 Sep 18:12(9):e10520. doi: 10.7759/cureus.10520.
32. Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Current cardiology reviews. 2013 Feb 1:9(1):15
33. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, D'Agati VD, Ferrario F, Haas M, Jennette JC, Joh K, Nast CC, Noël LH, Rijnink EC, Roberts ISD, Seshan SV, Sethi S, Fogo AB. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney international. 2018 Apr:93(4):789-796. doi: 10.1016/j.kint.2017.11.023.
34. Helget LN, Dillon DJ, Wolf B, Parks LP, Self SE, Bruner ET, Oates EE, Oates JC. Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis. Lupus science & medicine. 2021 Aug:8(1):. doi: 10.1136/lupus-2021-000489.
35. Umeda R, Ogata S, Hara S, Takahashi K, Inaguma D, Hasegawa M, Yasuoka H, Yuzawa Y, Hayashi H, Tsuboi N. Comparison of the 2018 and 2003 International Society of Nephrology/Renal Pathology Society classification in terms of renal prognosis in patients of lupus nephritis: a retrospective cohort study. Arthritis research & therapy. 2020 Nov 4:22(1):260. doi: 10.1186/s13075-020-02358-x.
36. Li GM, Li YF, Zeng QQ, Zhang XM, Liu HM, Feng JY, Shi Y, Wu BB, Xu H, Sun L. Lupus podocytopathy and antiphospholipid syndrome in a child with SLE: A case report and literature review. Frontiers in pediatrics. 2022:10():950576. doi: 10.3389/fped.2022.950576.
37. Mejia-Vilet JM, Zhang XL, Cruz C, Cano-Verduzco ML, Shapiro JP, Nagaraja HN, Morales-Buenrostro LE, Rovin BH. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. Journal of the American Society of Nephrology : JASN. 2020 Jun:31(6):1335-1347. doi: 10.1681/ASN.2019121285.
38. Gupta R, Yadav A, Aggarwal A. Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis. Clinical rheumatology. 2021 Mar:40(3):941-948. doi: 10.1007/s10067-020-05343-6.
39. Renaudineau Y, Chauveau D, Faguer S, Huart A, Ribes D, Pugnet G, Sailler L, Jamme T, Treiner E, Fortenfant F, Bost C, Carlé C, Belliere J. Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares. Journal of translational autoimmunity. 2024 Dec:9():100244. doi: 10.1016/j.jtauto.2024.100244.
40. Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, Nagaraja H, Indrakanti D, Rovin BH. Histologic versus clinical remission in proliferative lupus nephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2017 Aug 1:32(8):1338-1344. doi: 10.1093/ndt/gfv296
41. De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, Nash R, Rovin BH. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney international. 2018 Oct:94(4):788-794. doi: 10.1016/j.kint.2018.05.021. Epub 2018 Jul 23
42. Das U, Patel R, Guditi S, Taduri G. Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis. Lupus. 2021 May:30(6):876-883. doi: 10.1177/0961203321995251. Epub 2021 Feb 20
43. Malvar A, Alberton V, Lococo B, Lourenco M, Martinez J, Burna L, Besso C, Navarro J, Nagaraja HN, Khatiwada A, Wolf B, Rovin B. Remission of lupus nephritis: the trajectory of histological response in successfully treated patients. Lupus science & medicine. 2023 May:10(1):. doi: 10.1136/lupus-2023-000932
44. Malvar A, Alberton V, Lococo B, Ferrari M, Delgado P, Nagaraja HN, Rovin BH. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney international. 2020 Jan:97(1):156-162. doi: 10.1016/j.kint.2019.07.018.
45. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF,

Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Annals of the rheumatic diseases. 2020 Jun:79(6):713-723. doi: 10.1136/annrheumdis-2020-216924.

46. Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis. Human vaccines & immunotherapeutics. 2022 Nov 30:18(5):2072143. doi: 10.1080/21645515.2022.2072143.
47. Rúa-Figueroa Í, Salman-Monte TC, Pego Reigosa JM, Galindo Izquierdo M, Díez Álvarez E, Fernández-Nebro A, Román Ivorra JA, Calvo Penades I, Artaraz Beobide J, Calvo Alén J. Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus. Reumatologia clinica. 2024 Jun-Jul:20(6):312-319. doi: 10.1016/j.reumae.2024.03.002.
48. Carrión-Barberà I, Salman-Monte TC, Castell S, Castro F, Ojeda F, Carbonell J. Prevalence and factors associated with fatigue in female patients with systemic lupus erythematosus. Medicina clinica. 2018 Nov 9:151(9):353-358. doi: 10.1016/j.medcli.2017.12.007.
49. Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg DA, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. The Journal of rheumatology. 2019 May:46(5):492-500. doi: 10.3899/jrheum.180713.
50. Tsai WT, Chang HC, Wang CT, Chiang BL, Lin YT. Long-term outcomes in lupus patients receiving different renal replacement therapy. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2019 Aug:52(4):648-653. doi: 10.1016/j.jmii.2018.12.010.
51. Ruiz-Irastorza G, Dueña-Bartolome L, Dunder S, Varona J, Gomez-Carballo C, Dominguez-Cainzos J, Rodrigo-Manjon A, Bueno L, Richez C, Duffau P, Blanco P, Lazaro E. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmunity reviews. 2021 Oct:20(10):102898. doi: 10.1016/j.autrev.2021.102898.
52. Portalatin GM, Gebreselassie SK, Bobart SA. Lupus nephritis - An update on disparities affecting african americans. Journal of the National Medical Association. 2022 Jun:114(3S2):S34-S42. doi: 10.1016/j.jnma.2022.05.005.
53. Zhang H, Zhou M, Han X, Yang Y, Yu X. Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis: A PRISMA-compliant meta-analysis. Medicine. 2020 Aug 14:99(33):e21121. doi: 10.1097/MD.0000000000021121.
54. Jiang N, Li M, Zhang H, Duan X, Li X, Fang Y, Li H, Yang P, Luo H, Wang Y, Peng L, Zhao J, Wu C, Wang Q, Tian X, Zhao Y, Zeng X. Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study. Lupus science & medicine. 2022 Jan:9(1):. doi: 10.1136/lupus-2021-000617.
55. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N, ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. The New England journal of medicine. 2011 Nov 17:365(20):1886-95. doi: 10.1056/NEJMoa1014460.
56. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, Cuquet Pedragosa J, Ortiz-Santamaria V, Mauri Plana M, Cortés-Hernández J. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Annals of the rheumatic diseases. 2017 Sep:76(9):1575-1582. doi: 10.1136/annrheumdis-2016-210882.
57. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis and rheumatism. 2012 Apr:64(4):1215-26. doi: 10.1002/art.34359.
58. Jorge A, Wallace ZS, Lu N, Zhang Y, Choi HK. Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study. Annals of internal medicine. 2019 Feb 19:170(4):240-247. doi: 10.7326/M18-1570.
59. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J,

Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'Anci KE. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis & rheumatology (Hoboken, N.J.). 2020 Apr:72(4):529-556. doi: 10.1002/art.41191.

60. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Archives of internal medicine. 2000 Jul 10:160(13):2042-8
61. Athanassiou P, Athanassiou L. Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus. Life (Basel, Switzerland). 2023 Jul 1:13(7):. doi: 10.3390/life13071496.
62. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. The Lancet. Neurology. 2009 Nov:8(11):998-1005. doi: 10.1016/S1474-4422(09)70239-X.
63. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. The New England journal of medicine. 2020 Sep 17:383(12):1117-1128. doi: 10.1056/NEJMoa2001180.
64. Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, Isenberg DA, Doré CJ, Gordon C, Ehrenstein MR, BEAT-LUPUS Investigators. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial. Annals of internal medicine. 2021 Dec:174(12):1647-1657. doi: 10.7326/M21-2078.
65. Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.). 2024 Jan:76(1):59-67. doi: 10.1002/art.42657.
66. Xipell M, Lledó GM, Egan AC, Tamirou F, Del Castillo CS, Rovira J, Gómez-Puerta JA, García-Herrera A, Cervera R, Kronbichler A, Jayne DRW, Anders HJ, Houssiau F, Espinosa G, Quintana LF. From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Autoimmunity reviews. 2023 Oct:22(10):103404. doi: 10.1016/j.autrev.2023.103404.
67. Malvar A, Alberton V, Recalde C, Heguilen R. Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center. Lupus. 2023 Oct:32(12):1394-1401. doi: 10.1177/09612033231204070. Epub 2023 Sep 27
68. Mejia-Vilet JM, Turner-Stokes T, Houssiau F, Rovin BH. Kidney involvement in systemic lupus erythematosus: From the patient assessment to a tailored treatment. Best practice & research. Clinical rheumatology. 2023 Dec:37(4):101925. doi: 10.1016/j.berh.2023.101925.
69. Davies R, Peng SL, Lickliter J, McLendon K, Enstrom A, Chunyk AG, Blanchfield L, Wang N, Blair T, Thomas HM, Smith A, Dillon SR. A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults. Clinical and translational science. 2024 Nov:17(11):e70055. doi: 10.1111/cts.70055.
70. Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. Arthritis & rheumatology (Hoboken, N.J.). 2019 Mar:71(3):403-410. doi: 10.1002/art.40729.